TempraMed Announces LIFE Offering up to C$8 Million to Accelerate Global Expansion and Fulfilment of Forecasted Demand
Recent Highlights: Record sales: July 2026 sales were about US$522K1, the best month in the company's history, and August was about US$403K, its second-best. Run rate revenue of ~US$5.5M Sales for the first eight months of 2026 were about US$2.07M, already above the US$1.8M booked for all of 2025. Growing patent portfolio: 4 new global patents granted in 2026, for a total of Global distribut
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-20 7:00 AM EDT | TempraMed Technologies Ltd.
Custom Health Highlights Early Results with BKC Pain Specialists, Supporting Expansion of Chronic Pain Program
Custom Health's existing commercial program with BKC Pain Specialists & Regenerative Medicine Clinic in Ohio is demonstrating early results through the integration of in-home medication technology, pharmacy services and pharmacist-led clinical support for patients managing complex chronic pain. The program provides continuous visibility into patients' medication use and experiences between physician visits, enabling personalized patient engagement, pharmacist-
Technology, Pharmaceuticals, Health
2026-10-20 6:00 AM EDT | Custom Health Holdings Inc.
Herbal Dispatch Expands Offering with New Ontario and Saskatchewan Listings and Increased BC Portfolio
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, today announced that four of its Happy Hour SKUs have been listed with the Ontario Cannabis Store ("OCS"). The Company also provided an update on its British Columbia and Saskatchewan distribution. ONTARIO LISTINGS
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-10-20 6:00 AM EDT | Herbal Dispatch Inc.
Richards Group Inc. Announces October 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - October 19, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended October 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on October 30, 2026 and will be payable on November 13, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether suc
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-10-19 11:36 AM EDT | Richards Group Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA therapeutic platform, including its lead clinical ca
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-19 9:53 AM EDT | Phio Pharmaceuticals Corp.
BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - October 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced the appointment of Professor Richard B. Lipton, MD, as Co-Chair of its Scientific Advisory Board ("SAB"). Professor Lipton joins Professor Peter Goadsby, MD, PhD, FRS, whose appointment as Co-Chair was announced on
2026-10-19 8:00 AM EDT | BetterLife Pharma Inc.
Telescope Innovations to Participate in the Canadian Delegation to BIOPLUS-INTERPHEX Korea (BIX) 2026
Vancouver, British Columbia--(Newsfile Corp. - October 19, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of Physical AI systems, including Self-Driving Laboratories ("SDL"), enabling technologies, and services for the global pharmaceutical and high-value chemical industries, today announced that it has been chosen to join the Canadian business delegation to BIOPLUS-INTERPHEX Korea ("BIX
Technology, Chemical, Pharmaceuticals
2026-10-19 8:00 AM EDT | Telescope Innovations Corp.
CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine
Houston, Texas--(Newsfile Corp. - October 19, 2026) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced an expansion of its scientific research strategy focused on the intersection of endocannabinoid biology, precision medicine, and the development of intellectual property with potential biomedical applications. "We are witnessing a new era in the history of medicine: an era in which hum
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-10-19 7:00 AM EDT | Cannabis Bioscience International Holdings
Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
Montreal, Quebec--(Newsfile Corp. - October 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce two significant achievements at World ADC San Diego 2026, held October 12-15: winning the conference's Best Poster Award for its Accum&#
Biotechnology, Pharmaceuticals, Health
2026-10-19 3:15 AM EDT | Defence Therapeutics Inc.
Extendicare Announces October 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - October 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of October 2026, which is payable on November 16, 2026 to shareholders of record at the close of business on October 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare
Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-15 8:00 AM EDT | Extendicare Inc.
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced that Sheila Leitzinger has joined the Company as Head of Clinical Operations. In this role, Ms. Leitzinger will lead clinical trial planning and execution for the initial healthy volunteer study of BETR-001, the Company's lead ca
2026-10-15 8:00 AM EDT | BetterLife Pharma Inc.
Herbal Dispatch Ships 3,000 Units of 2026 Happy Hour Holiday Cannabis Calendar to BCLDB Following Sold-Out 2025 Edition
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, announced the sale and shipment of 500 cases (3,000 units) of its 2026 Happy Hour Holiday Cannabis Calendar 12 Days of Coast Mtn (the "Calendar") to the British Columbia Liquor Distribution Branch (the "BCLDB"). The Calendar will be s
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-10-15 6:00 AM EDT | Herbal Dispatch Inc.
TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint
Toronto, Ontario--(Newsfile Corp. - October 15, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has executed a definitive exclusive distribution agreement dated September 14, 2026 (the "Distribution Agreement") with OGM For Import Medicine and Medical Supplies (the "Distributor
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-15 3:05 AM EDT | TempraMed Technologies Ltd.
Unbuzzd Wellness Announces Loan Amendment, Warrant Cancellation, and Acquisition of Licensed Intellectual Property
Vancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™, announces that it entered into a second loan amending agreement (the "Loan Amendment") and a warrant cancellation and release agreement (the "Warrant Cancellation Agreement") with Quantum BioPharma Ltd. ("Quantum") on October 13, 2026. LOAN AMENDMENT The Loan Amendment extends the maturity date of the Company's secured loan
2026-10-14 4:56 PM EDT | Unbuzzd Wellness Inc.
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
Vancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced the formation of a Scientific Advisory Board ("SAB") to guide the clinical development of BETR-001. Professor Peter Goadsby, MD, PhD, FRS, has been appointed Co-Chair. The SAB will advise the Company's manage
2026-10-14 8:00 AM EDT | BetterLife Pharma Inc.
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization High-potency proprietary olive-derived Verbascoside composition demonstra
Biotechnology, Pharmaceuticals, Health
2026-10-13 7:00 AM EDT | BioHarvest Sciences Inc.
BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today issued a statement regarding a Notice of Civil Claim ("Claim") filed against the Company by Steven Sangha, an independent director of BetterLife, in the Supreme Court of British Columbia on October 8, 2026. As disclosed in the Company's unaudited interim financial statements and management's discussion and analysis for Jul
2026-10-09 3:00 PM EDT | BetterLife Pharma Inc.
Theralase(R) to Present at ThinkEquity Conference
Toronto, Ontario--(Newsfile Corp. - October 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of proprietary Energy-Activated Small Molecules ("EASMs") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company has been invited to present at the 2026 Thin
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-09 7:00 AM EDT | Theralase Technologies Inc.
TMC Group Reports Progress on Capacity Expansion Ahead of EANM 2026
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Earlier this year, TMC Group, a Canadian manufacturer of enriched stable isotopes, announced plans to increase production capacity by 50 percent. Today, the company is commissioning new production lines that are already producing material, marking an early milestone in that work. The company will be exhibiting at the European Association of Nuclear Medicine (EANM) Annual Congress in Vienna next week, where the team will c
Technology, Biotechnology, Chemical, Pharmaceuticals
2026-10-08 12:00 PM EDT | TMC Group